SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 29, 2003
OraSure Technologies, Inc.
(Exact name of issuer as specified in charter)
| Delaware | 001-16537 | 36-4370966 | ||
(State or Other Jurisdiction | (Commission file number) | (I.R.S. Employer |
220 East First Street
Bethlehem, Pennsylvania 18015-1360
(Address of principal executive offices)
(610) 882-1820
(Registrant’s telephone number, including area code)
| Item 5. | Other Events and Regulation FD Disclosure. |
OraSure Technologies, Inc. (the “Company”) issued a press release announcing the filing of an application with the U.S. Food and Drug Administration for pre-market approval of its OraQuick® Rapid HIV-1 Antibody Test for use in detecting HIV-1 antibodies in oral fluid and plasma samples. The information contained in the press release dated September 29, 2003 is incorporated herein by reference and attached to this Current Report on Form 8-K as Exhibit 99.
| Item 7. | Financial Statements and Exhibits |
(c) Exhibits
| Exhibit Number | Description | |
| 99 | Press Release dated September 29, 2003, announcing the filing of an application with the U.S. Food and Drug Administration for pre-market approval of its OraQuick® Rapid HIV-1 Antibody Test for use in detecting HIV-1 antibodies in oral fluid and plasma samples. | |
2
Signatures
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
ORASURE TECHNOLOGIES, INC. | ||||||||
| Date: | September 29, 2003 | By: | /s/ JACK E. JERRETT | |||||
Jack E. Jerrett Senior Vice President, General Counsel and Secretary | ||||||||
3
Index to Exhibits
| Exhibit Number | Description | |
| 99 | Press Release dated September 29, 2003, announcing the filing of an application with the U.S. Food and Drug Administration for pre-market approval of its OraQuick® Rapid HIV-1 Antibody Test for use in detecting HIV-1 antibodies in oral fluid and plasma samples. | |
4